IGF2BP2 binding to CPSF6 facilitates m6A-mediated alternative polyadenylation of PUM2 and promotes malignant progression in ovarian cancer

Abstract

Background: N6-methyladenosine (m6A) and alternative polyadenylation (APA) are common posttranscriptional regulatory mechanisms in eukaryotes. However, the m6A-dependent mechanism of APA regulation in ovarian cancer (OC) is still unclear.

Methods: The correlation between m6A and APA was analyzed by using RNA methylation sequencing of OC cells and single-cell sequencing of clinical samples from public databases. To explore the core regulatory factors that served as a bridge between m6A and APA, we employed RNA pull-down with biotin-labelled m6A, immunoprecipitation, mass spectrometry, western blot, protein purification and GST pull-down assays. Furthermore, the important target genes were screened by PAS-seq, eCLIP-seq, RIP-seq and meRIP-seq, and verified by RT-qPCR, 3′RACE, RNA stability, and dual luciferase reporter assays. Multiple phenotypic experiments were conducted to evaluate the function of the IGF2BP2-PUM2 axis in vitro and in vivo.

Results: This study found that the m6A was correlated with the APA and affected the 3′end processing in OC. The APA regulator CPSF6 tended to bind the m6A-modified transcripts in OC cells. Mechanistically, we demonstrated that the m6A reader IGF2BP2 KH1-4 domains could directly bind to the CPSF6-RS domain to regulate the 3′end processing of OC. Furthermore, sequencing revealed that the m6A was highly enriched in the 3′UTR near the proximal polyadenylation signal (PAS), which promotes the use of proximal PAS and leads to 3′UTR shortening. PUM2 was carried m6A and recognized by IGF2BP2, and CPSF6 was recruited at the proximal polyadenylation signal (pPAS) to generate the short-3′UTR transcript. The short PUM2 transcript was more stable than the long transcript, which promoted the malignant progression of OC.

Conclusions: We revealed a novel mechanism in which the m6A could regulate the APA processing of pre-mRNAs by crosstalk of IGF2BP2 and CPSF6. This study provides a potential strategy for the effective treatment of OC.

Keywords

alternative polyadenylation / CPSF6 / IGF2BP2 / N6-methyladenosine / ovarian cancer / PUM2

References

[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics. CA Cancer J Clin.2024; 74: 12-49.

[2] Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol.2024; 21: 389-400.

[3] Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther.2021; 6: 74.

[4] Shen Z, Gu L, Liu Y, et al. PLAA suppresses ovarian cancer metastasis via METTL3-mediated m(6)A modification of TRPC3 mRNA. Oncogene.2022; 41: 4145-4158.

[5] Yang L, Chen X, Qian X, Zhang J, Wu M, Yu A. Comprehensive analysis of the transcriptome-wide m6A methylome in endometrioid ovarian cancer. Front Oncol.2022; 12: 844613.

[6] Bi X, Lv X, Liu D, et al. METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246. Cell Death Discov.2021; 7: 237.

[7] Hua W, Zhao Y, Jin X, et al. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol Oncol.2018; 151: 356-365.

[8] Lyu Y, Zhang Y, Wang Y, et al. HIF-1α regulated WTAP overexpression promoting the Warburg effect of ovarian cancer by m6A-dependent manner. J Immunol Res.2022; 2022: 6130806.

[9] Li Y, Peng H, Jiang P, et al. Downregulation of methyltransferase-like 14 promotes ovarian cancer cell proliferation through stabilizing TROAP mRNA. Front Oncol.2022; 12: 824258.

[10] Jiang Y, Wan Y, Gong M, Zhou S, Qiu J, Cheng W. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-κB pathway. J Cell Mol Med.2020; 24: 6137-6148.

[11] Nie S, Zhang L, Liu J, et al. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res.2021; 40: 284.

[12] Bley N, Schott A, Müller S, et al. IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer. RNA Biol.2021; 18: 391-403.

[13] Müller S, Glaß M, Singh AK, et al. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic Acids Res.2019; 47: 375-390.

[14] Wang S, Li Z, Zhu G, et al. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis. J Ovarian Res.2021; 14: 154.

[15] Hsu KF, Shen MR, Huang YF, et al. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer.2015; 113: 414-424.

[16] Zhu W, Zhao L, Kong B, et al. The methylation modification of m6A regulators contributes to the prognosis of ovarian cancer. Ann Transl Med.2022; 10: 59.

[17] Li J, Wu L, Pei M, Zhang Y. YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells. J Ovarian Res.2020; 13: 111.

[18] Hao L, Wang JM, Liu BQ, et al. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim Biophys Acta Mol Cell Res.2021; 1868: 118878.

[19] Liu T, Wei Q, Jin J, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res.2020; 48: 3816-3831.

[20] Luo X, Xie L, Ma X, et al. IGF2BP3 recruits NUDT21 to regulate SPTBN1 alternative polyadenylation and drive ovarian cancer progression. Communicat Biol.2025; 8(1): 680.

[21] Tian B, Manley JL. Alternative polyadenylation of mRNA precursors. Nat Rev Mol Cell Biol.2017; 18: 18-30.

[22] Sun Y, Hamilton K, Tong L. Recent molecular insights into canonical pre-mRNA 3'-end processing. Transcription.2020; 11: 83-96.

[23] Chan S, Choi EA, Shi Y. Pre-mRNA 3'-end processing complex assembly and function. Wiley Interdiscip Rev RNA.2011; 2: 321-335.

[24] Luo X, Wei Q, Jiang X, et al. CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1. Cell Death Dis.2024; 15: 432.

[25] Huang H, Weng H, Sun W, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol.2018; 20: 285-295.

[26] Yalamanchili HK, Alcott CE, Ji P, Wagner EJ, Zoghbi HY, Liu Z. PolyA-miner: accurate assessment of differential alternative poly-adenylation from 3'Seq data using vector projections and non-negative matrix factorization. Nucleic Acids Res.2020; 48: e69.

[27] Van Nostrand EL, Pratt GA, Shishkin AA, et al. Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP). Nat Methods.2016; 13: 508-514.

[28] Geistlinger L, Oh S, Ramos M, et al. Multiomic analysis of subtype evolution and heterogeneity in high-grade serous ovarian Carcinoma. Cancer Res.2020; 80: 4335-4345.

[29] Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m(6)A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell Discov.2018; 4: 10.

[30] Ruepp MD, Aringhieri C, Vivarelli S, et al. Mammalian pre-mRNA 3' end processing factor CF I m 68 functions in mRNA export. Mol Biol Cell.2009; 20: 5211-5223.

[31] Dettwiler S, Aringhieri C, Cardinale S, Keller W, Barabino SM. Distinct sequence motifs within the 68-kDa subunit of cleavage factor Im mediate RNA binding, protein-protein interactions, and subcellular localization. J Biol Chem.2004; 279: 35788-35797.

[32] Wang R, Zheng D, Yehia G, Tian B. A compendium of conserved cleavage and polyadenylation events in mammalian genes. Genome Res.2018; 28: 1427-1441.

[33] Blair LP, Liu Z, Labitigan RL, et al. KDM5 lysine demethylases are involved in maintenance of 3'UTR length. Sci Adv.2016; 2: e1501662.

[34] Guo J, Zheng J, Zhang H, Tong J. RNA m6A methylation regulators in ovarian cancer. Cancer Cell Int.2021; 21: 609.

[35] Chang LL, Xu XQ, Liu XL, et al. Emerging role of m6A methylation modification in ovarian cancer. Cancer Cell Int.2021; 21: 663.

[36] Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell.2016; 63: 306-317.

[37] Ren F, Zhang N, Zhang L, Miller E, Pu JJ. Alternative polyadenylation: a new frontier in post transcriptional regulation. Biomark Res.2020; 8: 67.

[38] Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol.2017; 18: 31-42.

[39] Ke S, Alemu EA, Mertens C, et al. A majority of m6A residues are in the last exons, allowing the potential for 3' UTR regulation. Genes Dev.2015; 29: 2037-2053.

[40] Bartosovic M, Molares HC, Gregorova P, Hrossova D, Kudla G, Vanacova S. N6-methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3'-end processing. Nucleic Acids Res.2017; 45: 11356-11370.

[41] Molinie B, Wang J, Lim KS, et al. m(6)A-LAIC-seq reveals the census and complexity of the m(6)A epitranscriptome. Nat Methods.2016; 13: 692-698.

[42] Chen L, Fu Y, Hu Z, et al. Nuclear m(6) A reader YTHDC1 suppresses proximal alternative polyadenylation sites by interfering with the 3' processing machinery. EMBO Rep. 2022; 23: e54686.

[43] Yuan S, Xi S, Weng H, et al. YTHDC1 as a tumor progression suppressor through modulating FSP1-dependent ferroptosis suppression in lung cancer. Cell Death Differ.2023; 30: 2477-2490.

[44] Ghosh S, Ataman M, Bak M, et al. CFIm-mediated alternative polyadenylation remodels cellular signaling and miRNA biogenesis. Nucleic Acids Res.2022; 50: 3096-3114.

[45] Bejarano DA, Peng K, Laketa V, et al. HIV-1 nuclear import in macrophages is regulated by CPSF6-capsid interactions at the nuclear pore complex. Elife.2019; 8.

[46] Zhong Z, Ning J, Boggs EA, et al. Cytoplasmic CPSF6 regulates HIV-1 capsid trafficking and infection in a cyclophilin A-dependent manner. mBio.2021; 12.

[47] Tan S, Zhang M, Shi X, et al. CPSF6 links alternative polyadenylation to metabolism adaption in hepatocellular carcinoma progression. J Exp Clin Cancer Res.2021; 40: 85.

[48] Shi X, Ding K, Zhao Q, et al. Suppression of CPSF6 Enhances Apoptosis Through Alternative Polyadenylation-Mediated Shortening of the VHL 3'UTR in Gastric Cancer Cells. Front Genet. 2021: 707644.

[49] Kasowitz SD, Ma J, Anderson SJ, et al. Nuclear m6A reader YTHDC1 regulates alternative polyadenylation and splicing during mouse oocyte development. PLoS Genet.2018; 14: e1007412.

[50] Jang S, Cook NJ, Pye VE, et al. Differential role for phosphorylation in alternative polyadenylation function versus nuclear import of SR-like protein CPSF6. Nucleic Acids Res.2019; 47: 4663-4683.

[51] Rüegsegger U, Blank D, Keller W. Human pre-mRNA cleavage factor Im is related to spliceosomal SR proteins and can be reconstituted in vitro from recombinant subunits. Mol Cell.1998; 1: 243-253.

[52] Cardinale S, Cisterna B, Bonetti P, Aringhieri C, Biggiogera M, Barabino SM. Subnuclear localization and dynamics of the Pre-mRNA 3' end processing factor mammalian cleavage factor I 68-kDa subunit. Mol Biol Cell.2007; 18: 1282-1292.

[53] Matreyek KA, Yücel SS, Li X, Engelman A. Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS Pathog.2013; 9: e1003693.

[54] Zhu Y, Wang X, Forouzmand E, et al. Molecular mechanisms for CFIm-mediated regulation of mRNA alternative polyadenylation. Mol Cell.2018; 69: 62-74.e64.

[55] Goldstrohm AC, Hall TMT, McKenney KM. Post-transcriptional regulatory functions of mammalian pumilio proteins. Trends Genet.2018; 34: 972-990.

[56] Hu R, Zhu X, Chen C, Xu R, Li Y, Xu W. RNA-binding protein PUM2 suppresses osteosarcoma progression via partly and competitively binding to STARD13 3'UTR with miRNAs. Cell Prolif.2018; 51: e12508.

[57] Smialek MJ, Ilaslan E, Sajek MP, Jaruzelska J. Role of PUM RNA-binding proteins in cancer. Cancers (Basel).2021: 13.

[58] Xu L, Li Q, Wang Y, et al. m(6)A methyltransferase METTL3 promotes oral squamous cell carcinoma progression through enhancement of IGF2BP2-mediated SLC7A11 mRNA stability. Am J Cancer Res.2021; 11: 5282-5298.

[59] Li T, Hu PS, Zuo Z, et al. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer.2019; 18: 112.

[60] HafezQorani S, Lafzi A, de Bruin RG, et al. Modeling the combined effect of RNA-binding proteins and microRNAs in post-transcriptional regulation. Nucleic Acids Res.2016; 44: e83.

[61] Shi Y, Xiong X, Sun Y, et al. IGF2BP2 promotes ovarian cancer growth and metastasis by upregulating CKAP2L protein expression in an m(6) A-dependent manner. Faseb j.2023; 37: e23183.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.